On 20 November, the CEO Advisory Committee of the International Generic and Biosimilar Medicines Association (IGBA) convened to discuss how the generics and biosimilars sector can continue to deliver on its mission—ensuring affordable, safe, effective and quality-assured therapies for patients— in a shifting international landscape.
